|
|
Blood, 1 March 2006, Vol. 107, No. 5, pp. 1810-1817.
Prepublished online as a Blood First Edition Paper on October 25, 2005; DOI 10.1182/blood-2005-08-3229.
 Previous Article | Table of Contents | Next Article 
GENE THERAPY
Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice
Ciaran D. Scallan,
Haiyan Jiang,
Tongyao Liu,
Susannah Patarroyo-White,
Jurg M. Sommer,
Shangzhen Zhou,
Linda B. Couto, and
Glenn F. Pierce
From Avigen, Alameda, CA.
Long-term cures of hemophilia B have been achieved using AAV2 delivering the factor IX gene to the liver of adeno-associated virus (AAV)–naive hemophilic animals. However, the clinical success of this approach requires overcoming pre-existing AAV neutralizing antibodies prevalent in humans. To better define the inhibition of neutralizing antibodies on AAV2-mediated liver transduction, we developed an in vivo passive immunity model. SCID mice were first reconstituted to a defined neutralizing titer with pooled plasma-derived human immunoglobulin. AAV2-FIX vectors then were administered to the liver, and the transduction efficiency was measured by plasma FIX levels. Unexpectedly, AAV2 neutralizing titers lower than 1:10 were sufficient to neutralize 4 to 20 x 1012 vg/kg of AAV2 vectors in vivo, a capacity that was underestimated by in vitro neutralizing assays. We also evaluated strategies to evade neutralization, including the use of alternative delivery routes, infusion parameters, empty capsids, and alternative AAV serotypes 6 and 8. The results indicate that low AAV2 neutralizing titers can be inhibitory to the tested human and primate AAV vectors delivered into the circulatory system. Therefore, novel nonprimate AAV vectors or compartmentalized delivery may offer more consistent therapeutic effects in the presence of pre-existing AAV neutralizing antibodies.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
AAV immunity: more than meets the eye
- David Lillicrap
Blood 2006 107: 1741-1742.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
L. Yang, J. Jiang, L. M. Drouin, M. Agbandje-Mckenna, C. Chen, C. Qiao, D. Pu, X. Hu, D.-Z. Wang, J. Li, et al.
A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection
PNAS,
March 10, 2009;
106(10):
3946 - 3951.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Negrete and R. M. Kotin
Strategies for manufacturing recombinant adeno-associated virus vectors for gene therapy applications exploiting baculovirus technology
Brief Funct Genomic Proteomic,
July 16, 2008;
(2008)
eln034v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Grimm, J. S. Lee, L. Wang, T. Desai, B. Akache, T. A. Storm, and M. A. Kay
In Vitro and In Vivo Gene Therapy Vector Evolution via Multispecies Interbreeding and Retargeting of Adeno-Associated Viruses
J. Virol.,
June 15, 2008;
82(12):
5887 - 5911.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. R. Rodino-Klapac, L. G. Chicoine, B. K. Kaspar, and J. R. Mendell
Gene Therapy for Duchenne Muscular Dystrophy: Expectations and Challenges
Arch Neurol,
September 1, 2007;
64(9):
1236 - 1241.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Jiang, L. B. Couto, S. Patarroyo-White, T. Liu, D. Nagy, J. A. Vargas, S. Zhou, C. D. Scallan, J. Sommer, S. Vijay, et al.
Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy
Blood,
November 15, 2006;
108(10):
3321 - 3328.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. VandenDriessche
CAPitalizing on AAV
Blood,
July 1, 2006;
108(1):
4 - 5.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Jiang, D. Lillicrap, S. Patarroyo-White, T. Liu, X. Qian, C. D. Scallan, S. Powell, T. Keller, M. McMurray, A. Labelle, et al.
Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs
Blood,
July 1, 2006;
108(1):
107 - 115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
